AstraZeneca Retains 90% Of GI Business Despite Prilosec Generics

AstraZeneca is retaining 90% of its gastrointestinal business through increased use of the proton pump inhibitor Nexium, despite the availability of generic Prilosec in the U.S., CEO Tom McKillop said July 24